Net Profits At Bayer Improve 13.5% In 1996

17 March 1997

The Bayer group of Germany has announced that pretax profits for 1996grew 6.7% to 4.46 billion Deutschemarks ($7.59 billion). Net profits for the year were 2.75 billion marks, an increase of 13.5%. Earnings per share rose from 3.40 marks in 1995 to 3.85 marks, with a 1996 average of 708 million shares. Group annual sales were 48.61 billion marks, up 9%.

Group capital expenditure was 3.78 billion marks, compared with 3.2 billion marks a year earlier. R&D spending was 3.6 billion marks, a rise of 10.7%, and during the year the group spent 1.43 billion marks on acquistions.

At the parent company, Bayer AG, turnover in 1996 grew 0.9% to 18.19 billion marks. Net income rose 17.5% to 1.36 billion marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight